Tolvaptan in ADPKD Patients With Very Low Kidney Function

INTRODUCTION: Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) in TEMPO 3:4 and REPRISE trials. Tolvaptan effects in subjects with eGFR 15 to 24 ml/min per 1.73 m(2) were not investigated. This post hoc analysis retrospectively investigated eGFR decline in REPRISE versus an open-label, phase 3b extension trial (open-label extension [OLE] NCT02251275) in subjects who received placebo in REPRISE and tolvaptan in OLE with eGFR 15 to 24 and 25 to 29 ml/min per 1.73 m(2), respectively. METHODS: One data subset comprised subjects with OLE baseline eGFR 15 to 29 ml/min per 1.73 m(2) who had received placebo in REPRISE and began tolvaptan in OLE. The second comprised subjects who had received tolvaptan in REPRISE and were matched to REPRISE placebo-treated subjects for REPRISE baseline characteristics. Annualized eGFR slopes in REPRISE versus OLE were compared within the REPRISE placebo (i.e., placebo vs. tolvaptan treatment) and tolvaptan (i.e., 2 periods of tolvaptan treatment) subsets. RESULTS: Mean annualized eGFR slopes (ml/min per 1.73 m(2)) during tolvaptan treatment in OLE versus placebo treatment in REPRISE were −3.4 versus −5.2 for subjects with OLE baseline eGFR 15 to 29 (difference, 1.7; P < 0.001), −3.6 versus −5.4 with baseline eGFR 15 to 24 (difference, 1.8; P < 0.001), and −3.3 versus −4.9 with baseline eGFR 25 to 29 (difference, 1.6; P < 0.001). In REPRISE tolvaptan subjects who continued tolvaptan in OLE, treatment effect was maintained (no difference between mean annualized eGFR slopes). CONCLUSION: Initiating or maintaining tolvaptan therapy significantly delayed eGFR decline in subjects with baseline eGFR 15 to 24 and 25 to 29 ml/min per 1.73 m(2).